Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Reuters NewMedia - October 26, 2005
Aptivus, also called tipranavir, has been approved in combination with a low dose of Abbott Laboratories' Norvir, for the treatment of drug-resistant HIV infections, Boehringer said in a statement.
The drug will compete with rivals from GlaxoSmithKline, Roche, Pfizer and Merck.
Aptivus is a protease inhibitor, a class of drugs that works by blocking the action of an enzyme that cuts HIV proteins into the shorter sections which the virus needs to assemble copies of itself.
Boehringer said in June that it had received U.S. approval for the product.
051026
RE051029
Copyright © 2005 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .